Compare Cenovus Energy Inc (CVE) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Pfizer Inc — how do they compare? Cenovus Energy Inc trades at $31.49 (market cap $56.66B), while Pfizer Inc trades at $27.77 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 2.8× Cenovus Energy Inc's market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and Pfizer Inc for 158 Days on average.
| CVE | PFE | |
|---|---|---|
Market Cap | $56.66B | $159.59B |
Volume | 7,667,753 | 30,937,010 |
Sector | Energy | Health |
52-Week High | $33.92 | $29.02 |
52-Week Low | $15.85 | $23.67 |
Typical Hold Time | 46 Days | 158 Days |
Enterprise Value | $62.61B | $211.09B |
Dividend Yield | 2.03% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $31.49, up 0.8% today, with a bearish technical signal but strong fundamentals including a P/E of 12.14 and net income margin of 11.48%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q2 2026 met estimates. Cash flow from operations remains robust at $8.23B in 2025, though net cash flow was negative due to high capital expenditures. The stock is near its pivot point of $31, with support at $30 and resistance at $32.
Outlook: CVE offers value with attractive valuation ratios and solid profitability, but faces headwinds from volatile oil prices and capital-intensive operations. Analyst consensus is mixed with 40.7% buy ratings, suggesting cautious optimism amid energy sector uncertainty.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
